|
|
News Breaks
|
October 5, 2009
|
| 08:45 EDT |  | MIPI |
| theflyonthewall.com: | Molecular Insight presents Azedra 12-month efficacy data | | Molecular Insight Pharmaceuticals reported one-year follow-up data from a Phase I dose-escalation clinical study of Azedra demonstrating a positive safety profile and durable objective tumor responses in patients with neuroendocrine cancers, pheochromocytoma and paraganglioma. The study was designed to evaluate the safety and identify the maximum tolerated dose of Azedra, as well as to collect clinical data on efficacy. :theflyonthewall.com |
|
|
News For MIPI From The Last 14 Days Check below for free stories on MIPI the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
